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Recombinant human DNase I (rhDNase) has been shown to improve pulmonary function in patients treated 
for up to 6 months. A cohort of 52 cystic fibrosis patients with a FVC >40% predicted were enrolled into an 
open label study in order to evaluate longer-term effects of rhDNase. They received 2.5 mg rhDNase twice 
daily for 6 months followed by a 2-week wash-out period, and for the subsequent 18 months were treated with 
rhDNase once daily. Twenty-six male and 26 female patients with a mean FVC of 2.94 1 and FEV, of 1.47 1 
were recruited. Thirteen patients did not complete the study; there were seven deaths, three patients withdrew 
consent and three patients were lost to follow-up. Improvement in pulmonary function was seen following 
treatment and changes were evaluated as mean percent change from baseline. The maximum improvement 
occurred in the first month followed by a plateau at a lower level of improvement. The mean improvement in 
FEV, over the first month was 13.3% (range 12-14.1%), followed by a plateau at around 7.1% (range 
4.611.0%) for the subsequent 23 months. Mean FVC was improved by 12.03% (range 9.0-14.3%) over the 
first month and subsequently 4.2% (range - 2.2-10.2%). The effects on pulmonary function were similar for 
both treatment doses of rhDNase. There was also a steady improvement in weight from a mean of 54.2 kg to 
55.7 kg at the end of the study. Analysis of the results of only those patients who completed the full 2-yr 
treatment period show that changes in pulmonary function and weight were similar to those observed for the 
whole group. The death rate and adverse event profile were consistent with that seen in a cystic fibrosis 
population. This study confirms that longer-term treatment with rhDNase maintains the improvement in lung 
function, is associated with weight gain and has a good safety profile. 
Introduction 
Bronchopulmonary complications are responsible 
for much of the mortality and morbidity in cystic 
fibrosis (CF) (1,2). The chronic occlusion of airways 
by highly viscoelastic secretions, accompanied by 
bacterial colonization and persistence promotes the 
self perpetuating, neutrophil dominated, local 
immune response. The aggregating neutrophils 
release neutrophil elastase and oxygen radicals. These 
products are responsible for much of the lung dam- 
age and perpetuate the immune response by inducing 
chemoattractants, stimulating mucus secretion, and 
impairing ciliary clearance further. The neutrophil 
death that accompanies the process termed as ‘frus- 
trated phagocytosis’ contributes to the extracellular 
deoxyribonucleic acid (DNA) in CF sputum (3). The 
DNA is present in concentrations of 3314 mg ml - i 
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(4,5) and the interaction of polymerized DNA 
and mucous glycoproteins further exacerbates the 
abnormal rheology of airway secretions in CF. The 
viscoelastic secretions progressively impair pul- 
monary function by this pathogenic mechanism and 
also by occluding the bronchial tree per se. 
Current therapies in CF are aimed at promoting 
clearance of airway secretions, improving nutrition 
and reducing both inflammation and infection. The 
role of mucolytic agents aimed at mucous glycopro- 
teins has been controversial (6). Nebulized therapy 
may cause bronchospasm in some individuals (7) and 
the use of oral mucolytic agents has produced incon- 
sistent results (8-10). Recombinant human DNase I 
(rhDNase) depolymerizes extracellular DNA and 
reduces the viscoelasticity of purulent airway secre- 
tions. Initial Phase I studies have been encouraging 
(11,12) and two Phase II studies have confirmed that 
rhDNase effectively improves pulmonary function 
and that short-term treatment is safe (13,14). In the 
U.K. Phase II study (14), 71 stable CF patients with 
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mild to moderate pulmonary disease were random- 
ized to receive either placebo or 2.5 mg rhDNase 
twice daily. FEV, was improved by 13.3% on 
rhDNase compared to a mean change of - 0.2% for 
placebo. The Phase III double-blind placebo con- 
trolled study was conducted in 51 centres in North 
America (1.5). Nine hundred and sixty-eight CF 
patients older than 5 years of age with a FVC>40% 
predicted were randomized to receive either placebo, 
2.5 mg rhDNase once daily, or 2.5 mg rhDNase twice 
daily for 6 months. A modest reduction in the risk of 
exacerbations of respiratory symptoms requiring 
parenteral antibiotics was observed (reduction of 
22% in the rhDNase once daily group and 34% in the 
rhDNase twice daily group). Pulmonary function 
was also. improved by about 6% over the 6-month 
treatment period. 
The objectives of the present study were to evalu- 
ate the longer-term results of treatment with rhD- 
Nase. We have observed a cohort of 52 patients who 
had participated in the Phase II U.K. study who have 
received rhDNase over a 2-yr period and report the 
findings. 
Methods 
Fifty-two CF patients with mild to moderate pul- 
monary disease were treated with 2.5 mg rhDNase 
twice daily for 6 months followed by a 2-week 
wash-out period. Subsequently for the remaining 
period, patients received 2.5 mg rhDNase once daily. 
The patients were reviewed at regular intervals at a 
similar time of the day, and pulmonary function was 
performed at a similar time of the day according to 
American Thoracic Society Guidelines (16). Height 
and weight was also measured at each visit. Any 
adverse events, patient hospitalizations, or changes in 
medications were recorded. 
STATISTICAL ANALYSIS 
The results for pulmonary function are presented 
as mean percentage changes from baseline as mean 
(with range of means) unless otherwise stated. Con- 
version of pulmonary function variables to mean 
percentage changes from baseline allowed an assess- 
ment of the effect of treatment in a population with 
heterogeneous values for pulmonary function as 
suggested by the American Thoracic Society (17). 
Changes in lung function for the last 18 months on 
2.5 mg rhDNase once daily are calculated from the 
new baseline values (at 26 weeks) at the end of the 
2-week wash-out period. Descriptive statistics are 
used for the remaining parameters recorded and data 
that was found to have significant deviations from 
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Fig 1 Effects of recombinant human DNase 1 on FEV, 
and FVC in patients with cystic fibrosis (patients received 
2.5 mg rhDNase twice daily for first 6 months followed by a 
2-week wash-out period, and then 2.5 mg rhDNase once 
daily for the subsequent period). W, FEV,; 0, FVC. 
normality presented as medians (with inter-quartile 
ranges). 
Results 
Twenty-six male and 26 female CF patients with a 
mean FVC of 2.94 1 and FEV, of 1.47 I were 
observed over a 2-yr period. The age range for this 
cohort was 16-55 years. Treatment with rhDNase 
improved pulmonary function (Fig. 1). FEV, was 
improved by 13.3% (range 12-14.1%) and FVC 
improved by 12.03% (range 9.0-14.3%) in the first 
month. Subsequently, there was a plateau at 6.2% 
(range 4&7.8%) for FEV, and FVC at 7.2% (range 
5.1-10.2%) for the remaining 5 months on 2.5 mg 
rhDNase twice daily. Two weeks after discontinu- 
ation of rhDNase, FEV, was 5.7% and FVC 5.9% 
below baseline. Pulmonary function improved when 
the patients were recommenced on rhDNase. The 
mean change for FEV, over the last 18 months when 
patients received 2.5 mg rhDNase once daily was 
8.0% (range 5.1-11.0%) and FVC was improved by 
1.2% (range - 2.24.4%). A gradual improvement in 
weight was observed over the treatment period. Prior 
to therapy, mean weight was 54.2 (SEM & 1.2) kg and 
at the end of the 2-yr period was 55.7 (SEM f 1.48) kg 
(Fig. 2). Analysis of the results for only those patients 
who completed the 2-yr treatment period demon- 
strates that the relationship for both pulmonary 
function and weight are maintained, and not an 
artefact due to the loss of patients who did not 
respond to treatment or lighter patients. 
Respiratory tract infective exacerbations were the 
major adverse event recorded and there were 157 
such events. The data is skewed by four patients who 
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in the first month and was then maintained at a mean 
of 7.1% above baseline for the subsequent 23 months. 
Improvements in FVC were 12.0% for the first month 
and 4.2% for the remaining 23 months. Analysis of 
only those patients who completed the 2-yr treatment 
period shows that the changes are maintained and 
are not due to the possible artefact of losing patients 
who did not respond to therapy. Despite the limita- 
tions of an open-label study, these improvements 
which were maintained for up to 2 yr are considered 
important especially as lung function declines by 
34% annually in patients with established pul- 
monary infection (1819). In adult CF patients, 
weight gain is difficult to achieve and is a good 
indicator of patient well-being. In this cohort, an 
improvement in weight was observed following 
treatment with rhDNase. 
The incidence of respiratory tract infective exacer- 
bations and other pulmonary complications were 
consistent to those observed in a CF population (1,2), 
and comparable to the events observed in the North 
American Phase III placebo controlled study (15). 
However, the cohort of patients in the current study 
were older than those in the Phase III study and had 
more severe pulmonary disease. The Phase III study 
had also shown that there was no increase in serious 
respiratory adverse events such as haemoptysis, 
dyspnoea and pneumothorax. The incidence of 
death was also comparable in the control and 
treatment groups of the Phase III study. There were 
no unexpected serious respiratory adverse events in 
our cohort followed for 2 yr. The seven deaths 
occurred in patients with advanced lung disease 
(baseline FEV, ~30%). Baseline FEV, for the whole 
group was 41% predicted and the estimated mortality 
of patients with a FEV, ~30% is above 50% within 
2 yr (20). Further observation is important to see if 
survival and morbidity are influenced by therapy. 
The long-term results are encouraging as improve- 
ments in pulmonary function were maintained above 
baseline, an increase in weight was observed and drug 
treatment appeared to be safe. 
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